<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:5pt Arial, sans-serif; }
 .font1 { font:6pt Arial, sans-serif; }
 .font2 { font:7pt Arial, sans-serif; }
 .font3 { font:9pt Arial, sans-serif; }
 .font4 { font:14pt Times New Roman, serif; }

</style>
</head>
<body>
<p><span class="font4">J.P. Morgan</span></p>
<p><span class="font1">Isabella Y. Zhao. CFA</span></p>
<p><span class="font1">(852) 2800-8534</span></p>
<p><a href="mailto:lsabella.zhao@jprnorgan.com"><span class="font1">lsabella.zhao@jprnorgan.com</span></a></p>
<p><span class="font2" style="font-weight:bold;">Asia Pacific Equity Research</span></p>
<p><span class="font1">07 September 2016</span></p>
<div>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Key catalysts for the stock price:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Quarterly earnings beat</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Winning tenders in major provinces for key drugs and sales ramp up new products</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Approval and launch of human insulin</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Major M&amp;A in the hospital services sector</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Upside risks to our view:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Unexpected early approval of human insulin</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Better penetration in China market of Ama products</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Hospital services acquisition yields more synergies than expected</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Much better than expected sales performance from products due to tenders.</span></p></li></ul></td><td style="vertical-align:top;">
<p><span class="font3" style="font-weight:bold;">Downside risks to our view:</span></p>
<ul style="list-style:none;"><li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Unfavorable government policies on prices of healthcare products and services.</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Failure to gain from any future M&amp;A in terms of yield synergies and growth.</span></p></li>
<li>
<p><span class="font1">• &nbsp;&nbsp;&nbsp;Difficultly in exiting minority investments due to unfavorable market conditions.</span></p></li></ul></td></tr>
</table>
<p><span class="font1" style="font-weight:bold;">FY15A</span></p>
<p><span class="font1" style="font-weight:bold;">FY16E</span></p>
<p><span class="font1" style="font-weight:bold;">FY17E</span></p>
<p><span class="font1" style="font-weight:bold;">FY18E</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">Key financial metrics</span></p>
<p><span class="font1">Revenues(LC 000)</span></p>
<p><span class="font1">Revenue growth (%)</span></p>
<p><span class="font1">EBITDA (LC '000)</span></p>
<p><span class="font1">EBITDA margin (%)</span></p>
<p><span class="font1">Tax rate (%)</span></p>
<p><span class="font1">Net profit (LC '000)</span></p>
<p><span class="font1">EPS (LC)</span></p>
<p><span class="font1">EPS growth (%)</span></p>
<p><span class="font1">DPS (LC)</span></p>
<p><span class="font1">BOPS (LC)</span></p>
<p><span class="font1">Operating cash flow (LC 000)</span></p>
<p><span class="font1">Free cash flow (LC O00)</span></p>
</div><br clear="all">
<div>
<p><span class="font1">11,938,243</span></p>
<p><span class="font1">20.3%</span></p>
<p><span class="font1">1,605,294</span></p>
<p><span class="font1">13.4%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">12,502,163</span></p>
<p><span class="font1">4.7%</span></p>
<p><span class="font1">1,813,440</span></p>
<p><span class="font1">14.5%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">14,578,588</span></p>
<p><span class="font1">16.6%</span></p>
<p><span class="font1">2,201,400</span></p>
<p><span class="font1">15.1%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">17,023,790</span></p>
<p><span class="font1">16.8%</span></p>
<p><span class="font1">2,641,424</span></p>
<p><span class="font1">15.5%</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;text-decoration:underline;">Valuation and price target basis</span><span class="font1" style="font-weight:bold;">___________________</span></p>
<p><span class="font1">Our Deo-17 price target of HK$28.0 for Fosun H shares is based on DCF valuation.</span></p>
</div><br clear="all">
<div>
<p><span class="font1">12.8%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">14.9%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">15.0%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">15.0%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">2,369,839</span></p>
<p><span class="font1">0.92</span></p>
</div><br clear="all">
<div>
<p><span class="font1">2,870,661</span></p>
<p><span class="font1">1.06</span></p>
</div><br clear="all">
<div>
<p><span class="font1">3,268,415</span></p>
<p><span class="font1">1.21</span></p>
</div><br clear="all">
<div>
<p><span class="font1">3,733,775</span></p>
<p><span class="font1">1.39</span></p>
</div><br clear="all">
<div>
<p><span class="font1">30.3%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">15.6%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">14.0%</span></p>
</div><br clear="all">
<div>
<p><span class="font1">14.2%</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">Revenue mix in 2016 </span><span class="font1">E</span></p>
</div><br clear="all">
<div>
<p><span class="font1">0.34</span></p>
</div><br clear="all">
<div>
<p><span class="font1">0.39</span></p>
</div><br clear="all">
<div>
<p><span class="font1">0.44</span></p>
</div><br clear="all">
<div>
<p><span class="font1">0.51</span></p>
</div><br clear="all">
<div>
<p><span class="font2">87</span></p>
</div><br clear="all">
<div>
<p><span class="font1">9.5</span></p>
</div><br clear="all">
<div>
<p><span class="font1">10.9</span></p>
</div><br clear="all">
<div>
<p><span class="font1">12.1</span></p>
</div><br clear="all">
<div>
<p><span class="font1">686,576</span></p>
<p><span class="font1">(432,861)</span></p>
</div><br clear="all">
<div>
<p><span class="font1">1,353,589</span></p>
<p><span class="font1">118,063</span></p>
</div><br clear="all">
<div>
<p><span class="font1">3,494,094</span></p>
<p><span class="font1">2,5^,094</span></p>
</div><br clear="all">
<div>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font1">Interest cover (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">3.9</span></p></td><td style="vertical-align:top;">
<p><span class="font1">3.9</span></p></td><td style="vertical-align:top;">
<p><span class="font1">4.7</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Net margin (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">19.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">23.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">22.4%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Sales/assets (X)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">0.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">0.3</span></p></td><td style="vertical-align:top;">
<p><span class="font1">0.4</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Debt/equity (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">97.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">96.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">85.0%</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">Net debt/equity (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font1">30.7%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">37.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">23.1%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">ROE (%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">11.5%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">12.4%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">12.7%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Key model assumptions</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY15A</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY16E &nbsp;&nbsp;&nbsp;&nbsp;FY17E</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY18E</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Hospitals acquired</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font1">5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">5</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">ASP cut for drugs</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">5% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">5%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Manufacturing segment</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">margin</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;">
<p><span class="font1">15.2% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.4%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">15.6%</span></p></td></tr>
<tr><td colspan="4" style="vertical-align:middle;">
<p><span class="font0">Source: Company and J.P. IVbrgan estimates.</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Sensitivity analysis</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">EBITDA</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">EPS</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Sensitivity to</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY17E</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY18E &nbsp;&nbsp;&nbsp;&nbsp;FY17E</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY18E</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">1 ppt increase in GM</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">2.8%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">3.8% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5%</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">3.0%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">0.5ppt increase in selling</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">cost</span></p></td><td style="vertical-align:top;">
<p><span class="font1">■3.9%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">■9.1% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-3.5%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">■7.0%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">5% change in investment</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">gain</span></p></td><td style="vertical-align:top;">
<p><span class="font1">0.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">1.6% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">1.6%</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">5% increase in Sinopharrn</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">profit</span></p></td><td style="vertical-align:top;">
<p><span class="font1">0.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">1.6% &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.0%</span></p></td><td style="vertical-align:top;">
<p><span class="font1">1.5%</span></p></td></tr>
</table>
<p><span class="font1">219%</span></p>
<p><span class="font1">86.2%</span></p>
<p><span class="font1">16.0%</span></p>
<p><span class="font1">12.8%</span></p>
<p><span class="font0">Source: J.P. Morgan estimates.</span></p>
</div><br clear="all">
<div>
<p><span class="font1">3,158,479</span></p>
<p><span class="font1">2,227,479</span></p>
<p><span class="font1">5.6</span></p>
</div><br clear="all">
<div>
<p><span class="font1">0.4</span></p>
</div><br clear="all">
<div>
<p><span class="font0">Diagnose <sup>Hea#lcare </sup>products and medical device 18</span></p>
</div><br clear="all">
<div>
<p><span class="font0">Pharmaceut real distributor and retail 0%</span></p>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<p><span class="font0">Pharmaoeut reals manuheturi ng 71%</span></p>
</div><br clear="all">
<div>
<p><span class="font0">Source: Bloomberg, Company and J.P. IVbrgan estimates.</span></p>
<table border="1">
<tr><td colspan="2" style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">JPMe vs. consensus, change in estimates</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font1">FY18E</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">EPS (LC)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">FY17E</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font1">JPMe old</span></p></td><td style="vertical-align:top;">
<p><span class="font1">na</span></p></td><td style="vertical-align:top;">
<p><span class="font1">na</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font1">JPMe new</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">1.39</span></p></td><td style="vertical-align:middle;">
<p><span class="font1">1.57</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font2" style="font-style:italic;">% chÿ</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-style:italic;">na</span></p></td><td style="vertical-align:middle;">
<p><span class="font2" style="font-style:italic;">na</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">Consensus</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">1.40</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">1.55</span></p></td></tr>
</table>
<p><span class="font0">Source: Bloomberg, J.P. Morgan estimates.</span></p>
</div><br clear="all">
<div>
<p><span class="font1" style="font-weight:bold;">Comparative metrics</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">CMP LC</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1" style="font-weight:bold;">Mkt Cap ________</span><span class="font1" style="font-weight:bold;text-decoration:underline;">P/E(x)</span><span class="font1" style="font-weight:bold;">______________</span><span class="font1" style="font-weight:bold;text-decoration:underline;">EV/EBITDA (X)</span><span class="font1" style="font-weight:bold;">_____________</span><span class="font1" style="font-weight:bold;text-decoration:underline;">P/BV(x)</span><span class="font1" style="font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;YTD</span></p>
<p><span class="font1" style="font-weight:bold;">$Mn &nbsp;&nbsp;&nbsp;&nbsp;FY16E &nbsp;&nbsp;&nbsp;&nbsp;FY17E &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FY16E FY17E &nbsp;&nbsp;&nbsp;&nbsp;FY16E &nbsp;&nbsp;&nbsp;&nbsp;FY16E &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockperf.</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font1">FOSUN PHARMA-H (NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.9</span></p>
<p><span class="font1">SHANGHAI FOSUN-A(NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.56</span></p>
<p><span class="font1">BAJYUNSHANPH-H(NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.4</span></p>
<p><span class="font1">GUANGZHOU BAIY-A(NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.71</span></p>
<p><span class="font1">CSPC PHARMACEUTI</span></p>
<p><span class="font1">(NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.88</span></p>
<p><span class="font1">SHANGPHARM-A(NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.65</span></p>
<p><span class="font1">SHANGHAI PHARM-H</span></p>
<p><span class="font1">(NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.71</span></p>
<p><span class="font1">SINO BIOPHARM (NC) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3</span></p></td><td style="vertical-align:bottom;">
<p><span class="font1">7,986 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3</span></p>
<p><span class="font1">7,985 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.0</span></p>
<p><span class="font1">5,993 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7.1)</span></p>
<p><span class="font1">6,017 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1.1)</span></p>
<p><span class="font1">1,492 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;55.7</span></p>
<p><span class="font1">8,029 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31.7</span></p>
<p><span class="font1">5,992 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15.1)</span></p>
<p><span class="font1">5,066 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.9 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(24.5)</span></p></td></tr>
</table>
<p><span class="font0">Source: Boomberg; Price as of 03/02/2016</span></p>
</div><br clear="all">
<p><span class="font1">2</span></p>
</body>
</html>